Clinical Trial Update: Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing the efficacy and safety of NovoMix 30 in subjects with type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 30 (insulin aspart protamine fixed-dose combination)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED